ARGX vs. CRL: argenx vs. Charles River Laboratories Stock Comparison

Company Profile

argenx (ARGX) and Charles River Laboratories (CRL) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while CRL is classified in Life Sciences Tools & Services.

Charles River Laboratories (CRL) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while argenx (ARGX) is defensive at 0.45 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Charles River Laboratories (CRL) earns 1.27% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

argenx (ARGX) at 31.73% converts revenue to bottom-line profit above its industry’s benchmark range, while Charles River Laboratories (CRL) at 1.01% keeps roughly the typical share for its industry.

Both argenx (ARGX) at 36.27% and Charles River Laboratories (CRL) at 23.42% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Charles River Laboratories (CRL) at -0.85% is in the bottom quartile, showing a clear gap in revenue momentum.

argenx (ARGX) at 53.13% is around its peer norm for EPS growth, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range, a notably weak earnings reading.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Charles River Laboratories (CRL) shows current ratio of 1.41 against its industry benchmark, while argenx (ARGX) has no reading this period.

argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Charles River Laboratories (CRL) at 0.87 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Neither argenx (ARGX) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither argenx (ARGX) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

argenx (ARGX) at 32.12 is near its industry’s usual P/E ratio, while Charles River Laboratories (CRL) at 366.87 sits above its peer range — an unusually expensive price for CRL’s trailing earnings.

On P/S ratio, both argenx (ARGX) at 9.86 and Charles River Laboratories (CRL) at 4.07 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Charles River Laboratories (CRL) at 5.01 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.

Valuation Metrics